Exploring the use of a new imaging agent in prostate cancer surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This exploratory study investigates the biodistribution of a radio-guided surgery agent, 99mTc-PSMA-I&S, in patients with prostate cancer undergoing pelvic lymph node dissection. The study aims to determine how well this agent can identify cancerous lymph nodes during surgery by using a gamma probe to detect PSMA-expressing tissues. Patients will receive the agent intravenously and undergo multiple imaging scans to assess its accumulation in both normal and malignant tissues. The study also seeks to establish the optimal timing for surgery after administration of the imaging agent.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men with PCa (primary or recurrent disease)
* Men who received a 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) for staging or restaging
* Men with evidence of lymph nodes (LNs)-positive disease on 68Ga-PSMA-11 PET/CT
* Men who are scheduled for pelvic LN dissection (PLND)
* Men who can provide oral and written informed consent
* Men who can comply with study procedures

Exclusion Criteria:

* Patients who started any PCa treatment between study enrollment and surgery
* Technically inaccessible nodal location

Where it's running

• UCLA / Jonsson Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Jeremie Calais, MD — UCLA / Jonsson Comprehensive Cancer Center
• Study coordinator: Deepu Varughese
• Email: DVarughese@mednet.ucla.edu
• Phone: 310-206-7372

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metabolic strategies — time‑restricted eating, GLP‑1 medicines, and a heart‑healthy diet to protect heart and metabolic health during hormone therapy for prostate cancer

  This trial tests whether time‑restricted eating or GLP‑1 drugs (semaglutide or tirzepatide), combined with heart‑healthy diet counseling, can protect heart and metabolic health in men receiving androgen‑deprivation therapy for prostate cancer.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07202247

• Understanding NK Cell Function in Prostate Cancer Across Races

  This study tests whether natural killer (NK) cells behave differently in prostate cancer patients of diverse racial backgrounds by analyzing blood and tissue samples.

  Recruiting Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07910019

• MRI or CT planning to guide high-dose-rate prostate brachytherapy

  This trial tests whether adding an MRI to CT-based treatment planning for HDR prostate brachytherapy changes urinary side effects in men with localized prostate cancer.

  Recruiting at 3 sites Emory University · Atlanta, Georgia and 2 other locations · NCT07859722

• Targeted Early Detection for Men at High Genetic Risk for Prostate Cancer

  This study tests urinary biomarkers and PSA to see if they can improve early detection for men with a strong family or genetic risk for prostate cancer.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07645391

• Urine and MRI approach to find aggressive prostate cancer early

  This study tests whether a urine test called MPS2, paired with MRI, can better detect aggressive prostate cancer in men 50–75 at risk, possibly reducing unnecessary biopsies.

  Recruiting University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07526545

• GET FIT Together: a socially enhanced exercise program for older men with prostate cancer

  This program tests whether adding structured social support to supervised online exercise reduces cancer-related loneliness and improves mental and physical health in men 65 and older who have had prostate cancer.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT07504835

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.